Tango Therapeutics, Inc. · NASDAQ:TNGX
Crystal Adam sold 5,000 Tango Therapeutics, Inc. shares (Form 4)
Traded Nov 2, 2026 · Filed Nov 4, 2026
On Nov 2, 2026, Crystal Adam (President, R&D) sold 5,000 Tango Therapeutics, Inc. shares at an average US$22.42 for US$112K under a trading plan, leaving 115,743 shares. Filed Nov 4, 2026 (Form 4).
- Sold
- 5,000 shares
- Price
- US$22.42 average (US$22.26 to US$22.99)
- Value
- US$112K
- Holding after
- 115,743 shares
- Trading plan
- Yes (Made under a plan set in advance)
- Role
- President, R&D
The filing in full
| Date | Security | Transaction | Shares | Price | Holding after | Ownership |
|---|---|---|---|---|---|---|
| Nov 2, 2026 | Common Stock | Option exercise | 5,000 | US$2.91 | 120,743 | Direct |
| Nov 2, 2026 | Common Stock | Sale | 3,900 | US$22.26 | 116,843 | Direct |
| Nov 2, 2026 | Common Stock | Sale | 1,100 | US$22.99 | 115,743 | Direct |
Source
Download original · View original at SEC
Related
- Tango Therapeutics, Inc.
- Crystal Adam
- Tango Therapeutics, Inc. shareholders
- Form 4 · Crystal Adam · Nov 13, 2026
- Form 4 · Crystal Adam · Oct 5, 2026
- Form 4 · Crystal Adam · Sep 3, 2026
- Form 4 · Crystal Adam · Aug 5, 2026
- Form 4 · Crystal Adam · Jul 2, 2026
- Form 4 · Ketchum John B · Nov 19, 2026
- Schedule 13G/A · Farallon Capital Management, L.L.C. · Nov 16, 2026
- Schedule 13G/A · TCG Crossover GP II, LLC · Nov 16, 2026
- Schedule 13G/A · FMR LLC · Nov 6, 2026
- Form 4 · Newcomb Jessica · Nov 4, 2026